onr:"swepub:oai:lup.lub.lu.se:0da0906c-9ccb-413b-a705-2a29b86aefed"
Search: onr:"swepub:oai:lup.lub.lu.se:0da0906c-9ccb-413b-a705-2a29b86aefed" > Individualized prog...
- 1 of 1
- Previous record
- Next record
- To hitlist
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
-
- Cullen, Nicholas C. (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
-
- Leuzy, Antoine (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
-
- Palmqvist, Sebastian (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital
- show more...
- show less...
- (creator_code:org_t)
- 2020-11-30
- 2021
- English 10 s.
- In: Nature Aging. - : Springer Science and Business Media LLC. - 2662-8465. ; 1, s. 114-123
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included in the study. The primary outcomes were longitudinal cognition and conversion to Alzheimer’s disease (AD) dementia. A model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL), but not Aβ42/Aβ40, had the best prognosis performance of all models (area under the curve = 0.88 for 4-year conversion to AD in BioFINDER, validated in ADNI), was stronger than a basic model of age, sex, education and baseline cognition, and performed similarly to cerebrospinal fluid biomarkers. A publicly available online tool for individualized prognosis in MCI based on our combined plasma biomarker models is introduced. Combination of plasma biomarkers may be of high value to identify individuals with MCI who will progress to AD dementia in clinical trials and in clinical practice.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Geriatrik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Geriatrics (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Cullen, Nicholas ...
- Leuzy, Antoine
- Palmqvist, Sebas ...
- Janelidze, Shore ...
- Stomrud, Erik
- Pesini, Pedro
- show more...
- Sarasa, Leticia
- Allué, José Anto ...
- Proctor, Nichola ...
- Zetterberg, Henr ...
- Dage, Jeffrey L.
- Blennow, Kaj
- Mattsson-Carlgre ...
- Hansson, Oskar
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Neurology
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Geriatrics
- Articles in the publication
- Nature Aging
- By the university
- Lund University
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
